Scientists track cancer drug with special imaging in hopeful patients
NCT ID NCT05963867
Summary
This early study aims to understand how a new drug called BI 764532 moves through the body and into tumors in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard treatments. Participants receive the drug and then undergo special PET scans to see where it goes. The main goal is to gather information about the drug's distribution, not to treat the cancer directly, though some participants may continue receiving it if they seem to benefit and can tolerate it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC Locatie VUMC
RECRUITINGAmsterdam, 1081HV, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.